Haleos Labs Limi

Why is Haleos Labs Limited falling/rising?

As of 01-Jul, Haleos Labs Limited's stock price is rising to 1,645.05, reflecting a 13.49% increase. This growth is driven by strong short-term performance, increased investor interest, and significant outperformance compared to market benchmarks.

As of 01-Jul, Haleos Labs Limited's stock price is rising, currently at 1,645.05, reflecting a change of 195.5 or 13.49% increase. This upward movement is supported by several factors. The stock has outperformed its sector by 13.45% today and has been on a consecutive gain streak for the last two days, accumulating a total return of 20.54% during this period. Additionally, the stock opened with a gain of 4.17% today and reached an intraday high of Rs 1712, which is an increase of 18.11%.<BR><BR>The stock's performance over the past week shows a rise of 11.23%, contrasting with a slight decline of 0.09% in the Sensex. Year-to-date, Haleos Labs has delivered a robust return of 29.02%, significantly outperforming the Sensex, which has fallen by 9.74% during the same timeframe. Over the past year, the stock has generated a return of 38.24%, while the broader market has declined by 8.09%. <BR><BR>Moreover, the stock is trading above its moving averages across various timeframes, indicating a strong bullish trend. Investor participation has also increased, with delivery volume rising by 685.56% compared to the five-day average, suggesting heightened interest in the stock. <BR><BR>Despite some negative factors, such as a decline in profits and a relatively low Return on Capital Employed (ROCE), the attractive valuation compared to peers and consistent returns over the last three years contribute to the stock's rising price. Overall, the combination of strong short-term performance, increased investor interest, and favorable comparisons to market benchmarks are driving the rise in Haleos Labs Limited's stock price.

Which are the latest news on Haleos Labs Limi?

What does Haleos Labs Limi do?

Haleos Labs Limited is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally founded in 2006 and focusing on pharma since 2014. As of March 2026, it reported net sales of 75 Cr and a market cap of INR 415 Cr.

Overview:<BR>Haleos Labs Limited operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as "Potluri Real Estate Private Limited" in 2006, underwent several name changes, and became "SMS Lifesciences India Private Limited" in 2014 to focus on the pharma sector. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 75 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 415 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 23.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.11%<BR>- Debt-Equity: 0.51<BR>- Return on Equity: 8.11%<BR>- Price to Book: 1.95<BR><BR>Contact Details:<BR>Address: Plot No 19-III Road No 71, Opp Bharatiya Vidya Bhavan PSc Hyderabad Telangana : 500096<BR>Tel: 91-040-6628-8888<BR>Email: info@smslife.in<BR>Website: http://www.smslife.in

How big is Haleos Labs Limi?

As of 10th June, Haleos Labs Limited has a market capitalization of 415.00 Cr, with recent net sales of 333.79 Cr and a net profit of 17.32 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Haleos Labs Limited has a market capitalization of 415.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 333.79 Cr, while the sum of Net Profit for the same period is 17.32 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 196.56 Cr, and Total Assets are valued at 389.99 Cr.

Who are in the management team of Haleos Labs Limi?

The management team of Haleos Labs Limi includes T V V S N Murthy (Managing Director), P Sarath Kumar, Mannam Malakondaiah, Srinivas Samavedam, and P Venkata Subbarao (Independent Directors), Trupti Ranjan Mohanty (Company Secretary & Compliance Officer), Talluri Venkata Praveen (Executive Director), and Sudeepthi Gopin eedi (Whole-time Director). They oversee the company's operations and strategic direction.

The management team of Haleos Labs Limi includes the following individuals:<BR><BR>1. **T V V S N Murthy** - Managing Director<BR>2. **P Sarath Kumar** - Independent Director<BR>3. **Trupti Ranjan Mohanty** - Company Secretary & Compliance Officer<BR>4. **Talluri Venkata Praveen** - Executive Director<BR>5. **Sudeepthi Gopin eedi** - Whole-time Director<BR>6. **Mannam Malakondaiah** - Independent Director<BR>7. **Srinivas Samavedam** - Independent Director<BR>8. **P Venkata Subbarao** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Haleos Labs Limi?

Haleos Labs Limi's peers include Zim Laboratories, Amanta Healthcare, Influx Health, Bafna Pharma, Albert David, Valiant Laboratories, CCME Global, Jenburkt Pharma, and Transchem. In terms of performance, Bafna Pharma leads with a 1-year return of 132.56%, while Haleos Labs Limi has a return of 14.55%.

Peers: The peers of Haleos Labs Limi are Zim Laboratories, Amanta Healthcar, Influx Health., Bafna Pharma., Albert David, Valiant Laborato, CCME Global, Jenburkt Pharma, and Transchem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Influx Health. and Jenburkt Pharma, while Average management risk is found at Zim Laboratories, Amanta Healthcar, Albert David, and Transchem. Below Average management risk is noted at Bafna Pharma., Valiant Laborato, and CCME Global. Growth is rated as Good for Influx Health. and Valiant Laborato, while Average growth is seen at Zim Laboratories, Amanta Healthcar, Albert David, and Transchem. Below Average growth is reported for Bafna Pharma., Haleos Labs Limi, CCME Global, and the rest. Capital Structure is Excellent at Influx Health. and Albert David, Average at Zim Laboratories and Transchem, and Good at Bafna Pharma. and CCME Global, while Below Average is noted for Amanta Healthcar, Valiant Laborato, and the rest.<BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 132.56%, while Albert David has the lowest at -17.81%. Haleos Labs Limi's 1-year return of 14.55% is better than Albert David's but lower than Bafna Pharma.'s. Additionally, the six-month return is negative for Albert David, Valiant Laborato, and Transchem.

Should I buy, sell or hold Haleos Labs Limited?

Are Haleos Labs Limited latest results good or bad?

Haleos Labs Limited's latest results are concerning, with Q4 FY26 net sales declining 20.72% sequentially and 15.68% year-on-year, marking the lowest quarterly revenue recently. The net profit plummeted 85.19% to ₹0.44 crores, indicating significant operational challenges and margin pressures.

The latest results for Haleos Labs Limited are concerning. In Q4 FY26, the company reported net sales of ₹75.14 crores, which is a significant decline of 20.72% sequentially and 15.68% year-on-year. This marks the lowest quarterly revenue in recent periods. The operating profit margin, excluding other income, fell sharply to 5.54% from 14.82% in the previous quarter, indicating severe margin compression.<BR><BR>Furthermore, the net profit for the quarter was just ₹0.44 crores, down 85.19% compared to the same quarter last year. The profit after tax margin also deteriorated to a mere 0.45%, the lowest it has been in years. <BR><BR>Overall, the financial performance reflects significant operational challenges and margin pressures, suggesting that the company's situation is quite precarious at this time. Investors should be cautious, as the recent results indicate a troubling trend that raises questions about the company's ability to maintain profitability moving forward.

When is the next results date for Haleos Labs Limited?

Haleos Labs Limited will announce its results on 11 February 2026.

Haleos Labs Limited is scheduled to declare its results on 11 February 2026.

How has been the historical performance of Haleos Labs Limi?

Haleos Labs Limi showed improved financial performance in Mar'25, with net sales rising to 344.72 Cr and profit after tax increasing to 18.73 Cr, up from 6.33 Cr in the previous year. The company also reported enhanced operational efficiency, reflected in a significant rise in operating profit to 49.90 Cr.

Answer:<BR>The historical performance of Haleos Labs Limi shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Haleos Labs Limi's net sales increased from 305.96 Cr in Mar'24 to 344.72 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 344.72 Cr in Mar'25 from 305.96 Cr in the previous year. The raw material costs slightly decreased to 149.91 Cr in Mar'25, while employee costs rose to 59.54 Cr, reflecting a growing workforce. Total expenditure, excluding depreciation, increased to 299.68 Cr in Mar'25 from 274.84 Cr in Mar'24. Operating profit (PBDIT) saw a significant rise to 49.90 Cr in Mar'25, up from 34.95 Cr in Mar'24, indicating improved operational efficiency. Profit before tax surged to 26.19 Cr in Mar'25, compared to 9.85 Cr in the prior year, leading to a profit after tax of 18.73 Cr, up from 6.33 Cr. The consolidated net profit also increased to 20.11 Cr in Mar'25 from 9.09 Cr in Mar'24. The company's total liabilities slightly decreased to 389.99 Cr in Mar'25 from 391.33 Cr in Mar'24, while total assets also saw a decline to 389.99 Cr. Cash flow from operating activities improved to 34.00 Cr in Mar'25, up from 24.00 Cr in Mar'24, indicating better cash generation from core operations. Overall, Haleos Labs Limi demonstrated a positive trend in profitability and operational performance in the latest fiscal year.

Who are the top shareholders of the SMS Lifesciences?

The top shareholder of SMS Lifesciences is Annapurna Talluri, holding 24.56%. Individual investors own 25.55%, while the highest public shareholder is Harita Projects Private with 1.57%.

The top shareholders of SMS Lifesciences include the promoters, with Annapurna Talluri holding the largest stake at 24.56%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. Additionally, the highest public shareholder is Harita Projects Private, which holds 1.57%. Individual investors collectively own 25.55% of the shares.

Is SMS Lifesciences overvalued or undervalued?

As of May 30, 2025, SMS Lifesciences is considered undervalued with an attractive valuation grade, strong financial metrics, and a 67.7% return over the past year, significantly outperforming the Sensex.

As of 30 May 2025, the valuation grade for SMS Lifesciences has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its strong financial metrics, including a PE ratio of 19.39, an EV to EBITDA ratio of 10.55, and a PEG ratio of 0.16, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, SMS Lifesciences stands out with a similar PE ratio to its closest competitor, while also demonstrating a more favorable PEG ratio, indicating that it may offer better growth prospects at its current valuation. Notably, the company's return over the past year has significantly outperformed the Sensex, with a remarkable 67.7% increase compared to the index's 7.57%. This performance reinforces the argument for its undervaluation in the market.

What is the technical trend for SMS Lifesciences?

As of June 5, 2025, SMS Lifesciences shows a mildly bearish trend due to bearish daily moving averages and a weak weekly RSI, despite some bullish signals from the MACD and KST on longer time frames.

As of 5 June 2025, the technical trend for SMS Lifesciences has changed from mildly bullish to mildly bearish. The weekly MACD remains bullish, but the monthly MACD is mildly bearish, indicating a divergence in time frames. The weekly RSI is bearish, while the monthly RSI shows no signal, suggesting weakness in momentum. Daily moving averages are bearish, reinforcing the current negative sentiment. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly charts, but this is overshadowed by the bearish signals from the daily moving averages and the weekly RSI. The KST is bullish on both weekly and monthly time frames, providing some support. However, the OBV shows a mildly bearish trend on the weekly, contrasting with a bullish monthly outlook. Overall, the current stance is mildly bearish, driven primarily by the bearish daily moving averages and the weekly RSI.

Has SMS Lifesciences declared dividend?

Yes, SMS Lifesciences India Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of September 23, 2024. The company has shown strong price appreciation over various periods, with total returns reaching 353.05% over the last 5 years.

SMS Lifesciences India Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.12%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 11.55%, with a dividend return of 0%, resulting in a total return of 11.55%.<BR><BR>Over the past year, the price return reached 68.95%, while the dividend return was 0.19%, leading to a total return of 69.14%.<BR><BR>In the 2-year period, the price return was 146.28%, with a dividend return of 0.56%, culminating in a total return of 146.84%.<BR><BR>For the 3-year period, the price return stood at 83.85%, with a dividend return of 0.67%, resulting in a total return of 84.52%.<BR><BR>In the last 4 years, the price return was 105.78%, while the dividend return was 0.75%, leading to a total return of 106.53%.<BR><BR>Over the past 5 years, the price return was 351.06%, with a dividend return of 1.99%, resulting in a total return of 353.05%.<BR><BR>Overall, SMS Lifesciences has declared a dividend, contributing to a modest dividend yield, while the total returns over various periods indicate strong price appreciation, particularly over the longer term.